TAVIST-1
LOE ApproachingNDAORALTABLET
Approved
Feb 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAVIST-1 is an oral tablet approved by Novartis in 1977 with an unknown mechanism of action and indication profile. The product operates as a small molecule therapeutic, though specific clinical efficacy details are not currently available in the dataset.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), commercial teams are likely in transition or defensive positioning mode, suggesting limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TAVIST-1 currently shows zero linked job opportunities, reflecting its late-lifecycle status and minimal commercial expansion. Career roles on this product are primarily defensive, focused on maintaining market presence and managing compliance during the LOE transition.
Brand ManagerField Sales Representative
Worked on TAVIST-1 at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.